Ga-Young Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ga-Young Song has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Deok-Hwan Yang
Department of Hematology‐Oncology Chonnam National University Hwasun Hospital, Chonnam National University Medical School Hwasun Jeollanam‐do Republic of Korea
9 shared publications - Hyeoung-Joon Kim
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea
8 shared publications - Jae-Sook Ahn
Department of Hematology Oncology, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Republic of Korea
7 shared publications - Sung-Hoon Jung
Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
7 shared publications - Je-Jung Lee
Chonnam National University Hwasun Hospital
6 shared publications - Mihee Kim
Department of Hematology Oncology, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Republic of Korea
6 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (11) , e48025
Relapse of adult B-cell acute lymphoblastic leukemia in the bilateral lacrimal glands: A case report and literature review
Rationale: Extramedullary relapse of acute lymphoblastic leukemia (ALL) involving the orbit is uncommon, and lacrimal gland infiltration is particularly rare in adults. Bilateral lacrimal gland enlargement can be clinically nonspecific and may be misinterpreted as inflammatory or autoimmune disease, potentially delaying diagnosis. This case report describes a rare adult case of extramedullary relapse of B-cell ALL presenting as bilateral lacrimal gland enlargement following allogeneic hematopoietic stem cell transplantation (HSCT). Patient concerns: A 55-year-old woman presented with a 4-day history of a painless, palpable mass in the right upper eyelid. The patient had a history of Philadelphia chromosome-negative B-cell ALL and had previously undergone chemotherapy followed by allogeneic HSCT. Diagnoses: Orbital computed tomography demonstrated diffuse, heterogeneous enlargement of both lacrimal glands, more prominent on the right side. Incisional biopsy of the right lacrimal gland with immunohistochemical staining (terminal deoxynucleotidyl transferase positive and B-lineage markers positive) confirmed extramedullary relapse of B-cell ALL. Interventions: The patient received salvage chemotherapy followed by a 2nd allogeneic HSCT. Outcomes: Follow-up orbital computed tomography performed 6 months after treatment showed complete resolution of bilateral lacrimal gland enlargement without evidence of local progression. Lessons: Bilateral lacrimal gland enlargement in patients with a history of ALL may represent isolated extramedullary relapse, even in the absence of hematologic abnormalities. Early histopathologic confirmation is essential to prevent diagnostic delay and to enable timely systemic management in ALL patients.
- 13 March 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (11) , e48025
Open AccessRelapse of adult B-cell acute lymphoblastic leukemia in the bilateral lacrimal glands: A case report and literature review
Rationale: Extramedullary relapse of acute lymphoblastic leukemia (ALL) involving the orbit is uncommon, and lacrimal gland infiltration is particularly rare in adults. Bilateral lacrimal gland enlargement can be clinically nonspecific and may be misinterpreted as inflammatory or autoimmune disease, potentially delaying diagnosis. This case report describes a rare adult case of extramedullary relapse of B-cell ALL presenting as bilateral lacrimal gland enlargement following allogeneic hematopoietic stem cell transplantation (HSCT). Patient concerns: A 55-year-old woman presented with a 4-day history of a painless, palpable mass in the right upper eyelid. The patient had a history of Philadelphia chromosome-negative B-cell ALL and had previously undergone chemotherapy followed by allogeneic HSCT. Diagnoses: Orbital computed tomography demonstrated diffuse, heterogeneous enlargement of both lacrimal glands, more prominent on the right side. Incisional biopsy of the right lacrimal gland with immunohistochemical staining (terminal deoxynucleotidyl transferase positive and B-lineage markers positive) confirmed extramedullary relapse of B-cell ALL. Interventions: The patient received salvage chemotherapy followed by a 2nd allogeneic HSCT. Outcomes: Follow-up orbital computed tomography performed 6 months after treatment showed complete resolution of bilateral lacrimal gland enlargement without evidence of local progression. Lessons: Bilateral lacrimal gland enlargement in patients with a history of ALL may represent isolated extramedullary relapse, even in the absence of hematologic abnormalities. Early histopathologic confirmation is essential to prevent diagnostic delay and to enable timely systemic management in ALL patients.
- Open Access
- 12 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2610
Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is uncommon in Asia, and longitudinal genomic data from Asian cohorts are limited. We conducted serial whole-exome sequencing (WES) in a multicenter Korean cohort of newly diagnosed, elderly CLL treated with chlorambucil–obinutuzumab to evaluate mutational heterogeneity and clonal hematopoiesis of indeterminate potential (CHIP) during treatment and follow-up. Tumor-only variants were filtered, restricted to nonsynonymous or loss-of-function coding/splice-site mutations, and summarized as a binary patient-by-gene matrix for principal component analysis (PCA), trajectory analysis, and k-means clustering. CHIP was defined as ≥1 qualifying mutation in a prespecified CHIP gene set. Baseline PCA was more compact in patients with complete response at end of treatment, whereas partial response or progressive disease cases were more dispersed. PCA trajectories were compact and directionally consistent in complete responders, more dispersed in partial responders, and highly heterogeneous without a dominant direction in progressive disease. Clustering identified dispersed and compact clusters, and CHIP-associated mutations were enriched in the dispersed cluster (55.6% vs. 8.3%, Fisher’s exact p = 0.0086). In paired samples collected 3–5 months after end of treatment, CHIP status changed in some patients. Serial WES may provide complementary information to treatment response, although these observations require confirmation in larger cohorts.
- 12 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2610
Open AccessLongitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is uncommon in Asia, and longitudinal genomic data from Asian cohorts are limited. We conducted serial whole-exome sequencing (WES) in a multicenter Korean cohort of newly diagnosed, elderly CLL treated with chlorambucil–obinutuzumab to evaluate mutational heterogeneity and clonal hematopoiesis of indeterminate potential (CHIP) during treatment and follow-up. Tumor-only variants were filtered, restricted to nonsynonymous or loss-of-function coding/splice-site mutations, and summarized as a binary patient-by-gene matrix for principal component analysis (PCA), trajectory analysis, and k-means clustering. CHIP was defined as ≥1 qualifying mutation in a prespecified CHIP gene set. Baseline PCA was more compact in patients with complete response at end of treatment, whereas partial response or progressive disease cases were more dispersed. PCA trajectories were compact and directionally consistent in complete responders, more dispersed in partial responders, and highly heterogeneous without a dominant direction in progressive disease. Clustering identified dispersed and compact clusters, and CHIP-associated mutations were enriched in the dispersed cluster (55.6% vs. 8.3%, Fisher’s exact p = 0.0086). In paired samples collected 3–5 months after end of treatment, CHIP status changed in some patients. Serial WES may provide complementary information to treatment response, although these observations require confirmation in larger cohorts.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (18) , e81
Aerosolized Pentamidine Is an Effective Prophylaxis for Pneumocystis jiroveci Pneumonia in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation
Song GY, et al. J Korean Med Sci. 2026 Feb;41:e81. https://doi.org/10.3346/jkms.2026.41.e81
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (18) , e81
Open AccessAerosolized Pentamidine Is an Effective Prophylaxis for Pneumocystis jiroveci Pneumonia in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation
Song GY, et al. J Korean Med Sci. 2026 Feb;41:e81. https://doi.org/10.3346/jkms.2026.41.e81
- Open Access
Novel Wearable-Based Real-Time Temperature Monitoring in Hospitals for Febrile Adverse Events in Patients with Cancer: A Prospective Feasibility Study
Cancer remains a leading cause of mortality worldwide. Chemotherapy is effective but can cause febrile neutropenia, deplete neutrophils, and increase infection risk. Although timely fever detection is critical to prevent complications, periodic temperature monitoring has inherent limitations. Wearable devices (WDs) for real-time body temperature (RBT) monitoring are emerging as tools for early fever detection, though their clinical feasibility and usability remain unverified. This study assessed the clinical feasibility of a novel WD by comparing its temperature concordance and fever detection capability against a standard reference in patients with cancer. The RBT system’s clinical maturity, including its capacity for early fever detection and monitoring treatment-related changes, was evaluated. Furthermore, satisfaction among clinicians and patients was analyzed in a hospital setting. In this prospective study, patients with hematologic malignancies at high infection risk admitted to the Chonnam National University in Hwasun Hospital, South Korea, were enrolled. Data from 47 patients were analyzed to compare MT100D as WD (SEERS Technology Co., Ltd., South Korea) readings with axillary thermometers. Temperature concordance was evaluated using the intraclass correlation coefficient (ICC), and diagnostic performance was compared with the reference thermometer. The early fever detection performance of the MT100D was analyzed to evaluate the clinical effectiveness of the early response system. Usability was evaluated through a five-point Likert scale survey completed by clinical nurses. The MT100D demonstrated good agreement with the reference thermometer (mean difference: −0.19 ± 0.35 °C; ICC: 0.78). The RBT system achieved sensitivity, specificity, and area under the receiver operating characteristic curve values of 81.50%, 96.32%, and 96.60%, respectively. The early fever detection rate was 77.1%, with the RBT system detecting fever an average of 1.13 ± 1.28 h earlier than the reference. Usability and satisfaction assessments showed high patient satisfaction (mean 4.69 ± 0.5; range 4.57–4.80) and moderate clinician satisfaction (mean 3.63 ± 0.75; range 2.89–4.11). Among patients with cancer, including those at risk of febrile neutropenia, the MT100D demonstrated strong concordance with standard thermometry, enabling early fever detection. The RBT system shows promise for the early identification of neutropenic risk during chemotherapy.
Open AccessNovel Wearable-Based Real-Time Temperature Monitoring in Hospitals for Febrile Adverse Events in Patients with Cancer: A Prospective Feasibility Study
Cancer remains a leading cause of mortality worldwide. Chemotherapy is effective but can cause febrile neutropenia, deplete neutrophils, and increase infection risk. Although timely fever detection is critical to prevent complications, periodic temperature monitoring has inherent limitations. Wearable devices (WDs) for real-time body temperature (RBT) monitoring are emerging as tools for early fever detection, though their clinical feasibility and usability remain unverified. This study assessed the clinical feasibility of a novel WD by comparing its temperature concordance and fever detection capability against a standard reference in patients with cancer. The RBT system’s clinical maturity, including its capacity for early fever detection and monitoring treatment-related changes, was evaluated. Furthermore, satisfaction among clinicians and patients was analyzed in a hospital setting. In this prospective study, patients with hematologic malignancies at high infection risk admitted to the Chonnam National University in Hwasun Hospital, South Korea, were enrolled. Data from 47 patients were analyzed to compare MT100D as WD (SEERS Technology Co., Ltd., South Korea) readings with axillary thermometers. Temperature concordance was evaluated using the intraclass correlation coefficient (ICC), and diagnostic performance was compared with the reference thermometer. The early fever detection performance of the MT100D was analyzed to evaluate the clinical effectiveness of the early response system. Usability was evaluated through a five-point Likert scale survey completed by clinical nurses. The MT100D demonstrated good agreement with the reference thermometer (mean difference: −0.19 ± 0.35 °C; ICC: 0.78). The RBT system achieved sensitivity, specificity, and area under the receiver operating characteristic curve values of 81.50%, 96.32%, and 96.60%, respectively. The early fever detection rate was 77.1%, with the RBT system detecting fever an average of 1.13 ± 1.28 h earlier than the reference. Usability and satisfaction assessments showed high patient satisfaction (mean 4.69 ± 0.5; range 4.57–4.80) and moderate clinician satisfaction (mean 3.63 ± 0.75; range 2.89–4.11). Among patients with cancer, including those at risk of febrile neutropenia, the MT100D demonstrated strong concordance with standard thermometry, enabling early fever detection. The RBT system shows promise for the early identification of neutropenic risk during chemotherapy.
- Open Access
Clinical Implication of Sequential Circulating Tumor DNA Assessments for the Treatment of Diffuse Large B-Cell Lymphoma
Background/Objectives: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for non-invasive tumor monitoring in diffuse large B-cell lymphoma (DLBCL). Methods: In this study, 52 patients with newly diagnosed advanced-stage DLBCL treated with R-CHOP underwent serial ctDNA analysis at baseline, interim (after three cycles), and end of treatment. The prognostic significance of ctDNA dynamics was evaluated, and its predictive value was compared with the PET/CT response. Results: Targeted next-generation sequencing revealed baseline ctDNA in 98.1% of patients, with 74.7% concordance to tumor tissue genotyping. Higher baseline ctDNA levels correlated with elevated LDH, older age, and high IPI scores. A ≥2-log reduction in ctDNA at interim was significantly associated with improved overall survival (p = 0.004), though not with progression-free survival. Notably, combining interim ctDNA dynamics with PET/CT results enhanced the predictive accuracy for treatment outcomes, particularly among patients with partial metabolic responses. Conclusions: These findings support the clinical utility of ctDNA for dynamic risk assessment in DLBCL, and suggest that integrating ctDNA with imaging biomarkers may guide more personalized therapeutic strategies. Further validation using highly sensitive ctDNA assays is warranted to optimize its role in routine clinical practice.
Open AccessClinical Implication of Sequential Circulating Tumor DNA Assessments for the Treatment of Diffuse Large B-Cell Lymphoma
Background/Objectives: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for non-invasive tumor monitoring in diffuse large B-cell lymphoma (DLBCL). Methods: In this study, 52 patients with newly diagnosed advanced-stage DLBCL treated with R-CHOP underwent serial ctDNA analysis at baseline, interim (after three cycles), and end of treatment. The prognostic significance of ctDNA dynamics was evaluated, and its predictive value was compared with the PET/CT response. Results: Targeted next-generation sequencing revealed baseline ctDNA in 98.1% of patients, with 74.7% concordance to tumor tissue genotyping. Higher baseline ctDNA levels correlated with elevated LDH, older age, and high IPI scores. A ≥2-log reduction in ctDNA at interim was significantly associated with improved overall survival (p = 0.004), though not with progression-free survival. Notably, combining interim ctDNA dynamics with PET/CT results enhanced the predictive accuracy for treatment outcomes, particularly among patients with partial metabolic responses. Conclusions: These findings support the clinical utility of ctDNA for dynamic risk assessment in DLBCL, and suggest that integrating ctDNA with imaging biomarkers may guide more personalized therapeutic strategies. Further validation using highly sensitive ctDNA assays is warranted to optimize its role in routine clinical practice.
- Open Access
- 12 May 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (4) , 391-398
Chromosomal Rearrangements in 1,787 Cases of Acute Leukemia in Korea over 15 Years
DongGeun Son, M.D., Ho Cheol Jang, M.D., Young Eun Lee, Ph.D., Yong Jun Choi, M.D., Joo Heon Park, M.D., Ha Jin Lim, M.D., Hyun-Jung Choi, M.D., Ph.D., Hee Jo Baek, M.D., Ph.D., Hoon Kook, M.D., Ph.D., Mihee Kim, M.D., Ph.D., Ga-Young Song, M.D., Ph.D., Seo-Yeon Ahn, M.D., Ph.D., Sung-Hoon Jung, M.D., Ph.D., Deok-Hwan Yang, M.D., Ph.D., Je-Jung Lee, M.D., Ph.D., Hyeonug-Joon Kim, M.D., Ph.D., Jae-Sook Ahn, M.D., Ph.D., and Myung-Geun Shin, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0570
- 12 May 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (4) , 391-398
Open AccessChromosomal Rearrangements in 1,787 Cases of Acute Leukemia in Korea over 15 Years
DongGeun Son, M.D., Ho Cheol Jang, M.D., Young Eun Lee, Ph.D., Yong Jun Choi, M.D., Joo Heon Park, M.D., Ha Jin Lim, M.D., Hyun-Jung Choi, M.D., Ph.D., Hee Jo Baek, M.D., Ph.D., Hoon Kook, M.D., Ph.D., Mihee Kim, M.D., Ph.D., Ga-Young Song, M.D., Ph.D., Seo-Yeon Ahn, M.D., Ph.D., Sung-Hoon Jung, M.D., Ph.D., Deok-Hwan Yang, M.D., Ph.D., Je-Jung Lee, M.D., Ph.D., Hyeonug-Joon Kim, M.D., Ph.D., Jae-Sook Ahn, M.D., Ph.D., and Myung-Geun Shin, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0570
- Open Access
- 17 February 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (4) , 281-288
Prognostic Value of 18F-FDG PET in Primary Central Nervous System Lymphoma
Purpose of the Report: The usefulness of brain 18F-FDG PET/CT in primary central nervous system lymphoma (PCNSL) remains underexplored. This study investigated whether early metabolic responses in interim brain FDG PET/CT serve as a prognostic indicator of PCNSL treatment outcomes. Patients and Methods: This prospective study included 53 patients with PCNSL who underwent a high-dose methotrexate–based treatment. Brain FDG PET was performed at diagnosis (baseline PET) and after induction chemotherapy (interim PET), assessing interim PET parameters such as the highest maximum standardized uptake value (hSUVmax), sum of SUVmax (sumSUVmax), highest tumor-to-normal ratio (hTNRmax), sum of TNRmax (sumTNRmax), highest metabolic tumor volume (MTV) (hMTV), and sum of MTV (sumMTV) across all PET-positive lesions. Results: High interim hTNRmax (hazards ratio: 9.76, 95% confidence interval: 1.90–50.11, P = 0.01) was an independently significant predictor of poor progression-free survival in multivariate analysis. Patients with low interim hTNRmax (≤1.0) had a significantly longer median progression-free survival than those with high interim hTNRmax (>1.0) (25.0 vs 3.6 months, P < 0.001). Incorporating interim MRI-based clinical response assessments and hTNRmax allowed the classification of partial response subgroups with markedly different prognoses (P < 0.001). High interim hTNRmax (hazards ratio: 2.76, 95% confidence interval: 1.39–5.48, P = 0.004) was an independently significant predictor of poor overall survival in multivariate analysis. Conclusions: The hTNRmax measurement from interim brain FDG PET scans emerges as an important prognostic marker in PCNSL. These findings underscore the potential of interim FDG PET evaluations to refine response assessments and inform tailored therapeutic strategies.
- 17 February 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (4) , 281-288
Open AccessPrognostic Value of 18F-FDG PET in Primary Central Nervous System Lymphoma
Purpose of the Report: The usefulness of brain 18F-FDG PET/CT in primary central nervous system lymphoma (PCNSL) remains underexplored. This study investigated whether early metabolic responses in interim brain FDG PET/CT serve as a prognostic indicator of PCNSL treatment outcomes. Patients and Methods: This prospective study included 53 patients with PCNSL who underwent a high-dose methotrexate–based treatment. Brain FDG PET was performed at diagnosis (baseline PET) and after induction chemotherapy (interim PET), assessing interim PET parameters such as the highest maximum standardized uptake value (hSUVmax), sum of SUVmax (sumSUVmax), highest tumor-to-normal ratio (hTNRmax), sum of TNRmax (sumTNRmax), highest metabolic tumor volume (MTV) (hMTV), and sum of MTV (sumMTV) across all PET-positive lesions. Results: High interim hTNRmax (hazards ratio: 9.76, 95% confidence interval: 1.90–50.11, P = 0.01) was an independently significant predictor of poor progression-free survival in multivariate analysis. Patients with low interim hTNRmax (≤1.0) had a significantly longer median progression-free survival than those with high interim hTNRmax (>1.0) (25.0 vs 3.6 months, P < 0.001). Incorporating interim MRI-based clinical response assessments and hTNRmax allowed the classification of partial response subgroups with markedly different prognoses (P < 0.001). High interim hTNRmax (hazards ratio: 2.76, 95% confidence interval: 1.39–5.48, P = 0.004) was an independently significant predictor of poor overall survival in multivariate analysis. Conclusions: The hTNRmax measurement from interim brain FDG PET scans emerges as an important prognostic marker in PCNSL. These findings underscore the potential of interim FDG PET evaluations to refine response assessments and inform tailored therapeutic strategies.
- Open Access
Ensemble Deep Learning Model to Predict Lymphovascular Invasion in Gastric Cancer
Lymphovascular invasion (LVI) is one of the most important prognostic factors in gastric cancer as it indicates a higher likelihood of lymph node metastasis and poorer overall outcome for the patient. Despite its importance, the detection of LVI(+) in histopathology specimens of gastric cancer can be a challenging task for pathologists as invasion can be subtle and difficult to discern. Herein, we propose a deep learning-based LVI(+) detection method using H&E-stained whole-slide images. The ConViT model showed the best performance in terms of both AUROC and AURPC among the classification models (AUROC: 0.9796; AUPRC: 0.9648). The AUROC and AUPRC of YOLOX computed based on the augmented patch-level confidence score were slightly lower (AUROC: −0.0094; AUPRC: −0.0225) than those of the ConViT classification model. With weighted averaging of the patch-level confidence scores, the ensemble model exhibited the best AUROC, AUPRC, and F1 scores of 0.9880, 0.9769, and 0.9280, respectively. The proposed model is expected to contribute to precision medicine by potentially saving examination-related time and labor and reducing disagreements among pathologists.
Open AccessEnsemble Deep Learning Model to Predict Lymphovascular Invasion in Gastric Cancer
Lymphovascular invasion (LVI) is one of the most important prognostic factors in gastric cancer as it indicates a higher likelihood of lymph node metastasis and poorer overall outcome for the patient. Despite its importance, the detection of LVI(+) in histopathology specimens of gastric cancer can be a challenging task for pathologists as invasion can be subtle and difficult to discern. Herein, we propose a deep learning-based LVI(+) detection method using H&E-stained whole-slide images. The ConViT model showed the best performance in terms of both AUROC and AURPC among the classification models (AUROC: 0.9796; AUPRC: 0.9648). The AUROC and AUPRC of YOLOX computed based on the augmented patch-level confidence score were slightly lower (AUROC: −0.0094; AUPRC: −0.0225) than those of the ConViT classification model. With weighted averaging of the patch-level confidence scores, the ensemble model exhibited the best AUROC, AUPRC, and F1 scores of 0.9880, 0.9769, and 0.9280, respectively. The proposed model is expected to contribute to precision medicine by potentially saving examination-related time and labor and reducing disagreements among pathologists.
- 23 September 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (12) , 1810-1819
Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia
Secondary-type mutations (STMs), namely SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, and STAG2, are more frequently detected in secondary acute myeloid leukemia (AML) than in de novo AML. Whether de novo AML with STMs should be differently managed is, however, unclear. In 394 patients diagnosed with de novo AML who had a normal karyotype, the genetic profiling via targeted deep sequencing of 45 genes revealed 59 patients carrying STMs (STM+). The STM+ group showed shorter overall survival (OS) than the STM− group (5-year OS, 15.3 vs. 31.0%) (hazard ratio [HR]: 1.975, 95% confidence interval [CI]: 1.446–2.699, p < 0.001). Among the 40 STM+ patients who achieved CR, those who received allogeneic HCT (n = 15) showed better OS (5-year OS, 40.0 vs. 12.0%) (HR: 0.423, 95% CI: 0.184–0.975, p = 0.043) and relapse-free survival (5-year, 40.0 vs. 8.0%) (HR: 0.438, 95% CI: 0.189–1.015, p = 0.054) than those who received consolidation chemotherapy only. The cumulative incidence of relapse was lower in the patients who received allogeneic HCT (5-year, 33.3 vs. 60.0%) (HR: 0.288, 95% CI: 0.111–0.746, p = 0.011), and non-relapse mortality was similar between the two groups (p = 0.935). In conclusion, STM is an independent prognostic factor for adverse outcomes in AML that can be overcome by allogeneic HCT.
- 23 September 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (12) , 1810-1819
Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia
Secondary-type mutations (STMs), namely SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, and STAG2, are more frequently detected in secondary acute myeloid leukemia (AML) than in de novo AML. Whether de novo AML with STMs should be differently managed is, however, unclear. In 394 patients diagnosed with de novo AML who had a normal karyotype, the genetic profiling via targeted deep sequencing of 45 genes revealed 59 patients carrying STMs (STM+). The STM+ group showed shorter overall survival (OS) than the STM− group (5-year OS, 15.3 vs. 31.0%) (hazard ratio [HR]: 1.975, 95% confidence interval [CI]: 1.446–2.699, p < 0.001). Among the 40 STM+ patients who achieved CR, those who received allogeneic HCT (n = 15) showed better OS (5-year OS, 40.0 vs. 12.0%) (HR: 0.423, 95% CI: 0.184–0.975, p = 0.043) and relapse-free survival (5-year, 40.0 vs. 8.0%) (HR: 0.438, 95% CI: 0.189–1.015, p = 0.054) than those who received consolidation chemotherapy only. The cumulative incidence of relapse was lower in the patients who received allogeneic HCT (5-year, 33.3 vs. 60.0%) (HR: 0.288, 95% CI: 0.111–0.746, p = 0.011), and non-relapse mortality was similar between the two groups (p = 0.935). In conclusion, STM is an independent prognostic factor for adverse outcomes in AML that can be overcome by allogeneic HCT.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (1) , e2
Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma
Kim M, et al. J Korean Med Sci. 2021 Nov;37(1):e2. https://doi.org/10.3346/jkms.2022.37.e2
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (1) , e2
Open AccessDiagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma
Kim M, et al. J Korean Med Sci. 2021 Nov;37(1):e2. https://doi.org/10.3346/jkms.2022.37.e2